Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3-TKD Mutation”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Not applicableUnknownNCT03547258
What this trial is testing

Italian Non-Interventional Study of FLT3 Mutated AML Patients

Who this might be right for
AMLFLT3-ITD MutationFLT3-TKD Mutation
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 800
Testing effectiveness (Phase 2)Looking for participantsNCT06022003
What this trial is testing

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
AML, AdultRefractory AMLRelapsed Adult AML+2 more
French Innovative Leukemia Organisation 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT03836209
What this trial is testing

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
PrECOG, LLC. 181
Testing effectiveness (Phase 2)Temporarily pausedNCT04278768
What this trial is testing

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Curis, Inc. 366
Not applicableStudy completedNCT05193448
What this trial is testing

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

Who this might be right for
Refractory AMLRelapsed Adult AMLFLT3-TKD Mutation+1 more
French Innovative Leukemia Organisation 177
Not applicableAvailableNCT03620318
What this trial is testing

Individual Patient Compassionate Use of Crenolanib

Who this might be right for
FLT3-ITD MutationFLT3/TKD MutationPDGFR-Alpha D842V+1 more
Arog Pharmaceuticals, Inc.
Not applicableNo Longer AvailableNCT02624570
What this trial is testing

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Who this might be right for
Acute Myeloid Leukemia (AML) WithFLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)WithdrawnNCT02723435
What this trial is testing

Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

Who this might be right for
Acute Myeloid Leukemia With Gene MutationsAdult Acute Myeloid Leukemia in Remission
Stanford University